Phase 4
N=108
Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
Neuromuscular Blockade
Bottom Line
View on ClinicalTrials.gov: NCT03039543 ↗Enrolled (actual)
108
Serious AEs
0.0%
Results posted
May 2018
Primary outcome: Primary: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score — 16; 38 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Rocuronium (Drug); Sugammadex (Drug)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- Seoul National University Bundang Hospital
- Primary completion
- Nov 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Attaining a 5 (Optimal) Surgical Condition Score |
16; 38 | — |
| SECONDARY Incidence of Postoperative Residual Curarization |
0; 0 | — |
| SECONDARY Recovery Time (PACU Discharge) |
15; 15 | — |
| SECONDARY the Incidence of Desaturation |
0; 0 | — |
| SECONDARY Other Postoperative Adverse Events |
0; 0 | — |
Summary
Transurethral resection of the bladder tumor (TURB) for bladder tumor excision is the mainstream treatment. However, the beneficial effects of sugammadex after general anesthesia for TURB have not been thoroughly evaluated. Investigators hypothesized that deep NMB and the use of sugammadex as a reversal agent may be associated with better endoscopic surgical condition and recovery profile compared with moderate NMB during TURB.
This study was designed to compare patients with deep neuromuscular blockade (NMB) with moderate NMB during transurethral resection of the bladder tumor (TURB) in terms of surgical condition and postoperative recovery.
Eligibility Criteria
Inclusion Criteria
- Patients aged more than 18 years
- American Society of Anesthesiologists (ASA) physical status I and II
- scheduled to undergo elective Transurethral resection of the bladder tumor (TURB)
Exclusion Criteria
- history of neuromuscular, renal, or hepatic disease
- a body mass index (BMI) of C 30.0 kg/m2
- treatment with drugs known to interfere with neuromuscular function
Data sourced from ClinicalTrials.gov (NCT03039543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.